PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 478 participants.
Also called NCT07174375
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 478 participants
- Registry
-
NCT07174375
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07174375. Randomized; no masking; primary purpose treatment. Start 2025-09-15 (anticipated); primary completion 2027-12-15 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy
- Acronym
- PCSK9-PROVE
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- PCSK9 inhibitor
- Lead sponsor
- Nanfang Hospital, Southern Medical University
Record details
- Record id
cardio:ct-nct07174375- Content hash
01ae28bfca806fe7bfb7fa75094d58384aed291eb59d5338305531367980db67